Gilead Sciences (GILD) financials

Biotechnology · NASDAQ · Health Care

$170.68 +3.06% Close Oct 30, 2026 Live

Gilead Sciences revenue and earnings by year

Gilead Sciences's revenue was $29.4 billion in the fiscal year to December 31, 2025, up 2.4% from the year before. Net income was $8.51 billion, 28.9% of revenue. Since the fiscal year to December 31, 2016, revenue has shrunk 0.4% a year on average.

RevenueNet income
$10.0B$20.0B$30.0B
2016201720182019202020212022202320242025

Fiscal years, each labelled by the calendar year it ended in.

Income statement, the last 10 fiscal years

In billions of US dollars except per-share figures. Each column is a fiscal year, named by the month it ended.
Fiscal year toDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
Revenue29.428.827.127.327.324.722.422.126.130.4
Revenue growth2.4%6.0%-0.6%-0.1%10.6%10.0%1.5%-15.2%-14.1%—
Gross profit23.222.520.621.620.720.117.817.321.726.1
Gross margin78.8%78.3%76.0%79.3%75.8%81.5%79.2%78.1%83.3%86.0%
Operating income10.01.77.67.39.94.14.38.214.117.6
Operating margin34.0%5.8%28.0%26.9%36.3%16.5%19.1%37.1%54.1%58.0%
Net income8.50.55.74.66.20.15.45.54.613.5
Net margin28.9%1.7%20.9%16.8%22.8%0.5%24.0%24.7%17.7%44.4%
Diluted EPS$6.78$0.38$4.50$3.64$4.93$0.08$4.21$4.16$3.48$9.94
Free cash flow9.510.37.48.310.87.58.37.511.316.3

Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open GILD in Markets.

See also: GILD valuation and P/E history · GILD returns

No forecast, no recommendation. This page describes Gilead Sciences from published data; it is not advice to buy, sell or hold any security.

Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.